Chimeric RXFP1 and RXFP2 receptors highlight the similar mechanism of activation utilizing their N-terminal low-density lipoprotein class A modules

Frontiers in Endocrinology

Volumn 4, Issue NOV, 2013, Pages

  Bruell, Shoni ^a,b   Kong, Roy C K ^a,b   Petrie, Emma J ^b,c   Hoare, Brad ^a   Wade, John D ^a,d   Scott, Daniel J ^a,b   Gooley, Paul R ^b,c   Bathgate, Ross A D ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b Department of Biochemistry and Molecular Biology ^*  (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

GPCR; INSL3; Insulin like peptides; Relaxin; RXFP1; RXFP2; Signaling

Indexed keywords

EID: 84890305264     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2013.00171     Document Type: Article

References (26)

1. Stevens RC, Cherezov V, Katritch V, Abagyan R, Kuhn P, Rosen H, et al. The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov (2013) 12:25-34. doi:10.1038/nrd3859
2. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov (2006) 5:993-6. doi:10.1038/nrd2199
3. Hsu SY, Nakabayashi K, Nishi S, Kumagai J, Kudo M, Sherwood OD, et al. Activation of orphan receptors by the hormone relaxin. Science (2002) 295:671-4. doi:10.1126/science.1065654
4. Scott DJ, Layfield S, Yan Y, Sudo S, Hsueh AJ, Tregear GW, et al. Characterization of novel splice variants of LGR7 and LGR8 reveals that receptor signaling is mediated by their unique low density lipoprotein class A modules. J Biol Chem (2006) 281:34942-54. doi:10.1074/jbc.M602728200
5. Svendsen AM, Zalesko A, Kønig J, Vrecl M, Heding A, Kristensen JB, et al. Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1. Mol Cell Endocrinol (2008) 296:10-7. doi:10.1016/j.mce.2008.07.014
6. Svendsen AM, Vrecl M, Knudsen L, Heding A, Wade JD, Bathgate RAD, et al. Dimerization and negative cooperativity in the relaxin family peptide receptors. Ann N Y Acad Sci (2009) 1160:54-9. doi:10.1111/j.1749-6632.2009.03835.x
7. Bathgate RAD, Halls ML, Van Der Westhuizen ET, Callander GE, Kocan M, Summers RJ. Relaxin family peptides and their receptors. Physiol Rev (2013) 93:405-80. doi:10.1152/physrev.00001.2012
8. Hopkins EJ, Layfield S, Ferraro T, Bathgate RA, Gooley PR. The NMR solution structure of the relaxin (RXFP1) receptor lipoprotein receptor class A module and identification of key residues in the N-terminal region of the module that mediate receptor activation. J Biol Chem (2007) 282:4172-84. doi:10.1074/jbc.M609526200
9. Kong RC, Petrie EJ, Mohanty B, Ling J, Lee JC, Gooley PR, et al. The relaxin receptor (RXFP1) utilises hydrophobic moieties on a signalling surface of its N-terminal low density lipoprotein class A module to mediate receptor activation. J Biol Chem (2013) 288:28138-51. doi:10.1074/jbc.M113.499640
10. Fisher C, Beglova N, Blacklow SC. Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors. Mol Cell (2006) 22:277-83. doi:10.1016/j.molcel.2006.02.021
11. Halls ML, Bond CP, Sudo S, Kumagai J, Ferraro T, Layfield S, et al. Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8). J Pharmacol Exp Ther (2005) 313:677-87. doi:10.1124/jpet.104.080655
12. Kern A, Agoulnik AI, Bryant-Greenwood GD. The low-density lipoprotein class A module of the relaxin receptor (leucine-rich repeat containing G-protein coupled receptor 7): its role in signaling and trafficking to the cell membrane. Endocrinology (2007) 148:1181-94. doi:10.1210/en.2006-1086
13. Rosengren KJ, Lin F, Bathgate RA, Tregear GW, Daly NL, Wade JD, et al. Solution structure and novel insights into the determinants of the receptor specificity of human relaxin-3. J Biol Chem (2006) 281:5845-51. doi:10.1074/jbc.M511210200
14. Sudo S, Kumagai J, Nishi S, Layfield S, Ferraro T, Bathgate RA, et al. H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2. J Biol Chem (2003) 278:7855-62. doi:10.1074/jbc.M212457200
15. Yan Y, Scott DJ, Wilkinson TN, Ji J, Tregear GW, Bathgate RA. Identification of the N-linked glycosylation sites of the human relaxin receptor and effect of glycosylation on receptor function. Biochemistry (2008) 47:6953-68. doi:10.1021/bi800535b
16. Shabanpoor F, Hughes RA, Bathgate RAD, Zhang S, Scanlon DB, Lin F, et al. Solid-phase synthesis of Europium-labeled human INSL3 as a novel probe for the study of ligand-receptor interactions. Bioconjug Chem (2008) 19:1456-63. doi:10.1021/bc800127p
17. Shabanpoor F, Bathgate RA, Belgi A, Chan LJ, Nair VB, Wade JD, et al. Site-specific conjugation of a lanthanide chelator and its effects on the chemical synthesis and receptor binding affinity of human relaxin-2 hormone. Biochem Biophys Res Commun (2012) 420:253-6. doi:10.1016/j.bbrc.2012.02.141
18. Chen WB, Shields TS, Stork PJS, Cone RD. A colorimetric assay for measuring activation of Gs-and Gq-coupled signaling pathways. Anal Biochem (1995) 226:349-54. doi:10.1006/abio.1995.1235
19. Blacklow SC. Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. Curr Opin Struct Biol (2007) 17:419-26. doi:10.1016/j.sbi.2007.08.017
20. Yasui N, Nogi T, Takagi J. Structural basis for specific recognition of Reelin by its receptors. Structure (2010) 18:320-31. doi:10.1016/j.str.2010.01.010
21. Scott DJ, Rosengren KJ, Bathgate RA. The different ligand-binding modes of relaxin family peptide receptors RXFP1 and RXFP2. Mol Endocrinol (2012) 26:1896-906. doi:10.1210/me.2012-1188
22. Hossain MA, Rosengren KJ, Haugaard-Jonsson LM, Zhang S, Layfield S, Ferraro T, et al. The A-chain of human relaxin family peptides has distinct roles in the binding and activation of the different relaxin family peptide receptors. J Biol Chem (2008) 283:17287-97. doi:10.1074/jbc.M801911200
23. Wilkinson TN, Speed TP, Tregear GW, Bathgate RA. Coevolution of the relaxin-like peptides and their receptors. Ann N Y Acad Sci (2005) 1041:534-9. doi:10.1196/annals.1282.080
24. Wilkinson TN, Bathgate RA. The evolution of the relaxin peptide family and their receptors. Adv Exp Med Biol (2007) 612:1-13. doi:10.1007/978-0-387-74672-2_1
25. Nair VB, Samuel CS, Separovic F, Hossain MA, Wade JD. Human relaxin-2: historical perspectives and role in cancer biology. Amino Acids (2012) 43:1131-40. doi:10.1007/s00726-012-1375-y
26. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2013) 381:29-39. doi:10.1016/S0140-6736(12)61855-8